We expanded this analysis to additional cancer cell lines, where we saw robust dual HR/MMEJ inhibition by AZD1390 or the ATMi, KU60019, in TP53-mutant GBM, breast, and skin cancer cells but lesser inhibition in most TP53-WT cancer cell lines (Fig. S18). This evidence concerns the gene TP53 and skin cancer.